Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
UNLIMITED Watchlists, Portfolios, Screeners, and other Barchart tools with Barchart Premier. FREE 30 Day Trial
Stocks | Futures | Watchlist | News | More
or

Corcept Therapeutics (CORT)

Corcept Therapeutics (CORT)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Profile for [[ item.sessionDateDisplayLong ]]

Company Info

Corcept Therapeutics 101 REDWOOD SHORES PARKWAY REDWOOD CITY CA 94065 USA

www.corcept.com Employees: 352 P: 650-688-8803

Description:

Corcept is focused on the discovery, development and commercialization of drugs for the treatment of severe metabolic, psychiatric and oncology disorders which are associated with the activity of the hormone cortisol, also known as the stress hormone. Corcept's only marketed drug, Korlym (mifepristone), is approved for the once-daily oral treatment of hyperglycemia secondary to hypercortisolism in adult patients with endogenous Cushing's syndrome, suffering from type II diabetes or glucose intolerance and who have failed surgery or are not suitable for surgery.

Key Statistics

Overview:

Market Capitalization, $K 6,043,422
Enterprise Value, $K 5,907,872
Shares Outstanding, K 104,775
Annual Sales, $ 482,380 K
Annual Net Income, $ 106,140 K
Last Quarter Sales, $ 182,550 K
Last Quarter Net Income, $ 47,210 K
EBIT, $ 143,360 K
EBITDA, $ 136,590 K
60-Month Beta 0.45
% of Insider Shareholders 20.50%
% of Institutional Shareholders 93.61%
Float, K 83,296
% Float 79.50%
Short Volume Ratio 0.43

Growth:

1-Year Return 125.67%
3-Year Return 175.85%
5-Year Return 333.68%
5-Year Revenue Growth 91.99%
5-Year Earnings Growth 56.67%
5-Year Dividend Growth 0.00%

Per-Share Information:

Most Recent Earnings 0.41 on 10/30/24
Next Earnings Date N/A
Earnings Per Share ttm 1.26
EPS Growth vs. Prev Qtr 28.13%
EPS Growth vs. Prev Year 46.43%
Annual Dividend Yield 0.00%
Dividend Payout Ratio 0.00%

CORT Ratios

Ratio
Price/Earnings ttm 46.51
Price/Earnings forward 43.34
Price/Earnings to Growth N/A
Return-on-Equity % 24.54%
Return-on-Assets % 20.24%
Profit Margin % 22.00%
Debt/Equity 0.00
Price/Sales 12.73
Price/Cash Flow 61.18
Price/Book 9.61
Book Value/Share 6.10
Interest Coverage -1.68
Want to use this as
your default charts setting?
Save this setup as a Chart Templates
Switch the Market flag
for targeted data from your country of choice.
Open the menu and switch the
Market flag for targeted data from your country of choice.
Want Streaming Chart Updates?
Switch your Site Preferences
to use Interactive Charts
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.
Use your up/down arrows to move through the symbols.

Free Barchart Webinar